1月9日，A股市场震荡上行，沪指时隔10年重回4100点，A股创新药午后劲爆拉升，截至发稿，20CM创新药新物种——科创创新药ETF汇添富（589120） 涨超3%，反包昨日跌幅！ 科创创新药ETF汇添富（589120）标的指数成分股多数冲高，悦康药业大涨超10%，智翔金泰涨超8%、微芯生物涨超6%，荣昌生物涨超4%，艾力斯、百 利天恒涨超2%，君实生物、百济神州等涨幅居前。 【科创创新药ETF汇添富（589120）标的指数前十大成分股】 | 序号 | 代码 | 名称 | 申万一级行业 | 涨跌幅 | 估自权重 | | --- | --- | --- | --- | --- | --- | | 1 | 688235 | 百济神州-U | 医药生物 | 1.77% | 10.55% | | 2 | 688578 | 艾力斯 | 医药生物 | 2.18% | 9.04% | | 3 | 688506 | 自利天恒 | 医药生物 | 2.84% | 8.82% | | 4 | 688180 | 君实生物-U | 医药生物 | 1.73% | 6.49% | | ਟ | 688266 | 泽璟制药-U | 医药生物 ...

证券日报网讯 1月8日，微芯生物发布公告称，公司近日获国家药监局签发《药物临床试验批准通知 书》，同意公司产品西奥罗尼胶囊开展临床试验。 （文章来源：证券日报） ...

1月8日晚，金力永磁(300748)发布2025年度业绩预告，预计归属于上市公司股东的净利润为6.60亿-7.60 亿元，比上年同期增长127%-161%。 温氏股份：2025年净利润同比预降40.73%-46.12% 1月8日晚，温氏股份(300498)发布公告称，预计2025年归属于上市公司股东的净利润为50.00亿-55.00亿 元，比上年同期下降40.73%-46.12%。 新开源：拟以4000万–5000万元回购公司股份 1月8日晚，新开源(300109)发布公告称，拟以4000万-5000万元回购公司股份，回购价格上限为25.77元/ 股。预计回购股份数量约为155.22万股至194.02万股，占公司当前总股本比例为0.40%至0.32%。 金力永磁：2025年净利润同比预增127%-161% 复星医药：控股子公司药品注册申请获受理 1月8日晚，复星医药(600196)发布公告称，控股子公司复星万邦就丁二酸复瑞替尼胶囊（SAF-189）再 次递交药品注册申请获国家药品监督管理局受理，该新药用于间变性淋巴瘤激酶（ALK）阳性的局部 晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。该新药为创新型小分 ...

智通财经APP讯，微芯生物(688321.SH)公告，公司近日收到国家药品监督管理局签发的《药物临床试 验批准通知书》，同意公司产品西奥罗尼胶囊开展联合特瑞普利单抗及化疗一线治疗转移性胰腺导管腺 癌的临床研究。 ...

西奥罗尼是公司自主研发、拥有全球知识产权保护的全新化学结构小分子抗肿瘤1类原创新药。西奥罗 尼具有多通路的抗肿瘤作用机制，通过抑制AuroraB、CSF1R和VEGFR/PDGFR/c-Kit等多个激酶靶点， 发挥全面的抗胰腺癌作用。西奥罗尼通过对AuroraB的作用抑制胰腺癌细胞增殖，与化疗药吉西他滨联 用对胰腺癌生长具有明显的协同抑制效应；西奥罗尼通过抑制PDGFR、CSF1R和DDR1，降低肿瘤组织 中浸润的MDSC和TAM，抑制成纤维细胞活性，从而改善抑制性肿瘤微环境，可实现与化疗及免疫治疗 药物的联合增效。 格隆汇1月8日丨微芯生物(688321.SH)公布，公司近日收到国家药品监督管理局签发的《药物临床试验 批准通知书》，同意公司产品西奥罗尼胶囊开展临床试验。 西奥罗尼在胰腺癌的II期临床患者随访阶段数据显示，西奥罗尼联合标准AG化疗（白蛋白紫杉醇和吉 西他滨）一线治疗晚期胰腺导管腺癌的客观缓解率、疾病控制率和无进展生存期均优于AG化疗历史数 据，且患者的安全性和耐受性良好。结合西奥罗尼的作用机制及在II期研究中取得的初步疗效，预期在 联合PD-1单抗及化疗后能够进一步改善晚期胰腺癌患者的临床疗效 ...

微芯生物公告，公司产品西奥罗尼胶囊获得国家药监局签发的《药物临床试验批准通知书》，同意开展 临床试验。西奥罗尼胶囊适应症为联合PD-1单抗及化疗一线治疗转移性胰腺导管腺癌患者。西奥罗尼 是公司自主研发的全新化学结构小分子抗肿瘤1类原创新药，具有多通路的抗肿瘤作用机制。 ...

Core Viewpoint - Micron Biomedical has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration [2] Group 1 - The clinical trial application for Xioroni capsules has been officially accepted, indicating progress in the drug development process [2] - This development highlights the company's commitment to advancing innovative treatments in oncology [2]

Core Viewpoint - Micron Biologics (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed drug, Xioroni capsules, for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration (NMPA) [1] Group 1: Drug Development - Xioroni is a novel small molecule anti-tumor drug with a unique chemical structure, developed independently by the company and protected by global intellectual property rights [1] - The drug exhibits a multi-pathway anti-tumor mechanism by inhibiting multiple kinase targets, including Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit, providing comprehensive anti-pancreatic cancer effects [1] - Xioroni has shown significant synergistic inhibitory effects on pancreatic cancer growth when used in combination with the chemotherapy drug Gemcitabine [1] Group 2: Clinical Trial Results - Phase II clinical follow-up data indicates that Xioroni combined with standard AG chemotherapy (albumin-bound paclitaxel and Gemcitabine) has better objective response rates, disease control rates, and progression-free survival compared to historical data of AG chemotherapy [2] - The safety and tolerability of Xioroni in patients are reported to be good [2] - The drug is expected to further improve clinical efficacy and extend survival time for patients with advanced pancreatic cancer when combined with PD-1 monoclonal antibodies and chemotherapy [2]

Core Viewpoint - Microchip Biotech (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The company has recently announced the acceptance of its clinical trial application [1] - The clinical trial is focused on a new drug aimed at treating a specific type of cancer, namely metastatic pancreatic ductal adenocarcinoma [1]